C07C 237/34
Having the nitrogen atom of the carboxamide group bound to an acyclic
Official title: having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
C07C237/34 (Having the nitrogen atom of the carboxamide group bound to an acyclic) appears on 70 US grants and 78 published applications in this corpus.
Search patents in C07C- Granted patents
- 70
- Published applications
- 78
- Assignees
- 77
- Inventors
- 311
- Latest grant
- 7 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 1 |
| 2002 | 5 | 0 |
| 2003 | 4 | 2 |
| 2004 | 0 | 2 |
| 2005 | 0 | 4 |
| 2006 | 3 | 5 |
| 2007 | 2 | 2 |
| 2008 | 3 | 7 |
| 2009 | 3 | 2 |
| 2010 | 2 | 2 |
| 2011 | 2 | 2 |
| 2012 | 2 | 4 |
| 2013 | 2 | 6 |
| 2014 | 2 | 4 |
| 2015 | 4 | 4 |
| 2016 | 2 | 2 |
| 2017 | 2 | 5 |
| 2018 | 2 | 0 |
| 2019 | 2 | 7 |
| 2020 | 4 | 3 |
| 2021 | 4 | 3 |
| 2022 | 2 | 3 |
| 2023 | 1 | 1 |
| 2024 | 2 | 2 |
| 2025 | 1 | 3 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof7 Oct 2025US 12,435,051 B2Vivozon Inc.
- Benzoylglycine derivatives and methods of making and using same1 Oct 2024US 12,103,904 B2Duke University
- Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof13 Aug 2024US 12,060,339 B2Vivozon Inc.
- 2-(substituted benzene matrix) aromatic formate FTO inhibitor, preparation method therefor, and applications thereof17 Jan 2023US 11,555,009 B2Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Radioactive compound for diagnosis of malignant melanoma and use thereof22 Nov 2022US 11,504,439 B2Industry Foundation of Chonnam National University
- Irreversible inactivators targeting araf/mek complexes7 May 2026US 2026/0125376 A1
- Compounds and methods for liquid phase oligonucleotide synthesis1 Jan 2026US 2026/0001904 A1
- Targeting an eukaryotic initiation factor 2 alpha kinase to regulate translation under stress12 Jun 2025US 2025/0186373 A1The Johns Hopkins University
- Thiostrepton-inspired compounds for treatment of cancer and preparation thereof8 May 2025US 2025/0144078 A1RS Oncology, LLC
- Substituted benzamides and their use in therapy27 Feb 2025US 2025/0064761 A1Pharmacyl AB
Most cited
By later US patents
- Aniline derivatives35US 7,879,863 B2Ajinomoto Co., Inc. · 2011
- Salicylamide-lanthanide complexes for use as luminescent markers34US 6,406,297 B1The Regents of the University of California · 2002
- Substituted diarylamines as MEK inhibitors34US 7,001,905 B2Warner-Lambert Company · 2006
- Substituted benzamides, their production and their use as cysteine protease inhibitors33US 6,436,925 B1Abbott Laboratories · 2002
- Protease inhibiting succinic acid derivatives25US 5,545,640 ABio-Mega/Boehringer Ingeleheim Research Inc. · 1996